PT-141 FOR MEN: A NEW DRUG TO TREAT ERECTILE DYSFUNCTION AND LOW LIBIDO

Introduction 

Erectile dysfunction (ED) and other male sexual dysfunctions can significantly impact quality of life and relationships. While phosphodiesterase-5 inhibitors (PDE5is) like sildenafil (Viagra®) are effective for many men, a substantial minority (estimated 30–40%) see little or no improvement with these standard therapies. Moreover, PDE5is act peripherally on blood vessels and require sexual stimulation to be effective, which may not address issues of low sexual desire or psychological barriers to arousal. PT-141, known generically as bremelanotide, is an emerging therapy that works through a completely different mechanism. Originally approved as an on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide is now being explored off-label for men with ED and related conditions. This comprehensive post presents clinical evidence to explain how PT-141 works in men, its safety, dosing, effectiveness, and how it compares with existing treatments. 

What is PT-141 (Bremelanotide)? 

Bremelanotide is a synthetic peptide drug and the first of a new class: melanocortin receptor agonists. It was derived from research on melanotan II – a peptide initially developed for sunless tanning that unexpectedly induced sexual arousal and erections in early tests. Bremelanotide is essentially a refined metabolite of melanotan II, designed to maximize sexual effects while minimizing side effects. In 2019, the U.S. FDA approved bremelanotide (brand name Vyleesi®) as an as-needed injectable treatment for women with HSDD. Though not officially approved for men yet, growing clinical data suggest PT-141 may help men with ED or low libido, especially those who do not respond to or cannot take existing therapies. In the sections below, we delve into how PT-141 works in males, its clinical evidence, safety profile, dosing strategies, ways to gauge its effectiveness, combination uses, ideal candidates, and current availability. 

Mechanism of Action in Males 

Central Pathway Activation: Unlike Viagra and other ED pills that act on blood vessels, PT-141 works on the brain. Bremelanotide is a melanocortin receptor agonist, primarily targeting the MC4 receptor in the hypothalamus – a key brain region for sexual function. By activating melanocortin receptors, bremelanotide triggers a cascade of neural signals that ultimately stimulate sexual arousal and the erectile response. In simple terms, bremelanotide initiates arousal and erections via the central nervous system, rather than directly relaxing penile blood vessels. This central mechanism sets it apart from PDE5 inhibitors, which facilitate an erection only when a man is already sexually stimulated. 

Dopamine Release and Sexual Arousal: Activation of MC4 receptors by PT-141 is thought to increase the release of dopamine in the medial preoptic area of the hypothalamus, a region that governs sexual desire and arousal. Dopamine is a neurotransmitter strongly associated with sexual excitement. By raising dopamine levels in key brain pathways, PT-141 can heighten libido (sexual desire) and initiate the physiological processes leading to an erection. This central dopaminergic effect means PT-141 has the potential to help men who have low sexual desire or psychological ED, in addition to those with purely vascular erectile problems. 

Initiating vs. Facilitating Erections: Because PT-141 acts on the brain’s sexual centers, it can “initiate” an erection even in the absence of direct sexual stimulation. This is different from PDE5is (like sildenafil or tadalafil), which only enhance the quality of an erection in response to arousal signals that must already be present. In fact, early studies noted that bremelanotide could produce erections in men without visual sexual stimuli by purely central activation. Clinicians sometimes describe this as a more “natural” arousal pathway – PT-141 essentially works upstream, prompting the body’s own arousal signals, whereas PDE5is work downstream by improving blood flow to an already aroused penis. 

Melanocortin Receptors and Effects: Bremelanotide is non-selective among melanocortin receptors 1 through 5 (except MC2), but its pro-sexual effects are primarily linked to MC4 receptor stimulation. The MC4 receptor plays a role in sexual function for both men and women, as evidenced by increased sexual desire observed when it’s activated. Notably, melanocortin receptors also affect other processes like pigmentation and appetite. MC1 receptors control skin pigmentation, which explains one rare side effect of PT-141: transient skin darkening or freckling in some individuals. MC4 activation in the brain, meanwhile, leads to neuronal signals down the spinal cord to the pelvic organs, resulting in penile erection via increased parasympathetic activity and possibly some direct pro-erectile effects on penile tissue.I mportantly, bremelanotide’s mechanism does not rely on nitric oxide, so it can work even when nitric oxide pathways (targeted by Viagra and others) are insufficient. 

In summary, PT-141’s mechanism in males can be thought of as “flipping the switch” in the brain that turns on sexual desire and erection signals. It leverages the body’s central pathways (melanocortin and dopamine systems) to produce an erection and heighten libido, rather than directly affecting the penis’ blood vessels. This novel approach positions bremelanotide as a complementary therapy to existing ED drugs and a promising option for men whose sexual dysfunction has a significant central or psychological component. 

Clinical Evidence for PT-141 in Men 

Research on bremelanotide for male sexual dysfunction spans over 15 years, including clinical trials in men with ED and more recent real-world clinical experience. Below we review the key evidence: 

Early Clinical Trials (Intranasal Bremelanotide) 

Initial studies of PT-141 in men utilized an intranasal spray formulation. In the mid-2000s, several Phase II trials were conducted in men with erectile dysfunction, including those with psychogenic ED and those who had not responded to Viagra or similar drugs. One large placebo-controlled trial (presented at the AUA meeting in 2007) tested intranasal bremelanotide in 726 men with ED (average age 55) over 12 weeks. Doses ranged from 5 mg up to 15 mg given as a nasal spray on-demand ~45 minutes before sexual activity. The findings were promising:

• Improved Erectile Function: Men receiving bremelanotide (at doses 7.5 mg and above) showed statistically significant improvements in erectile function scores (IIEF) compared to placebo.In particular, doses of 7.5, 10, 12.5, and 15 mg were all associated with better International Index of Erectile Function outcomes than placebo.This indicated a dose-dependent efficacy, with higher intranasal doses yielding better erections. Notably, some men achieved sufficient rigidity for intercourse with PT-141 even if they had failed prior PDE5 therapy.
• Enhanced Sexual Confidence and Satisfaction: This trial also assessed men’s Self-Esteem and Relationship (SEAR) scores – a psychological metric of sexual confidence and satisfaction. Bremelanotide users reported significant improvements in sexual self-confidence and relationship satisfaction versus baseline.According to lead investigator Dr. Stanley Althof, these results suggested PT-141 meaningfully improved the psychosocial aspects of sexual function, not just the physical ability to get an erection.In other words, men felt more assured and satisfied in their sexual encounters when using PT-141.

One randomized controlled trial published in the Journal of Urology (Safarinejad et al., 2008) specifically looked at men with ED who did not respond to sildenafil (Viagra). In this trial, 342 men with sildenafil-failure ED were given either intranasal PT-141 (10 mg dose) or placebo on demand over ~4–8 weeks.The outcomes demonstrated a clear benefit of bremelanotide:

• About 33.5% of men on bremelanotide achieved a “positive clinical response” (improved erections sufficient for intercourse) compared to only 8.5% on placebo. This was a statistically significant difference (p = 0.03). These responders had previously failed to achieve satisfactory erections with Viagra, highlighting PT-141’s potential as a “salvage” therapy for PDE5i non-responders.
• Men on PT-141 reported greater intercourse satisfaction and an increased number of successful coitus episodes, as measured by diary and the Intercourse Satisfaction domain of the IIEF. This indicates not only were erections improved, but the overall sexual experience was better.
• The authors concluded that bremelanotide can be an effective alternative treatment for ED, with a “potentially broad patient base,” though they called for further studies. (It’s worth noting that this particular study’s data were later subject to an expression of concern, so results should be interpreted with some caution. Nonetheless, the weight of evidence from multiple studies supports similar positive outcomes.)

Synergy with PDE5 Inhibitors (Combination Therapy): The unique mechanisms of PT-141 and PDE5 inhibitors raised the question: what if you combine them for men who need extra help achieving an erection? A small exploratory study in 2005 did just that. Researchers gave 32 men with ED a combination of intranasal PT-141 (either 7.5 or 10 mg) plus oral sildenafil (50 or 100 mg), then used a RigiScan device to objectively measure erectile rigidity over 6 hours.Impressively, adding PT-141 to sildenafil increased the duration of erectile activity by over five-fold compared to sildenafil alone. On average, men had erections lasting 5.3 times longer when using the combo versus Viagra by itself. The enhancement was statistically significant in most dose comparisons, and no serious adverse events occurred. This early data signaled a powerful synergy: PDE5is improve the vascular response while PT-141 boosts central arousal signals, together yielding a stronger and longer-lasting erection. 

Clinical Note: Because bremelanotide initiates erections via central pathways and sildenafil maintains them via local blood flow, their combination addresses two aspects of ED. Co-therapy could be especially useful in difficult cases – for example, a man with significant performance anxiety (who struggles to get an erection started) and some vascular ED (who struggles to maintain it). The combination approach is currently under more rigorous study in Phase II trials (discussed below). 

Shift to Subcutaneous Injection and Recent Studies 

Intranasal bremelanotide was eventually discontinued in development because some men experienced dose-related increases in blood pressure (more on safety later). By 2008, the manufacturer (Palatin Technologies) halted nasal formulation trials and pivoted to a subcutaneous injection route, which showed fewer cardiovascular side effects. The injection form was tested and refined in women (leading to the 2019 FDA approval for HSDD), but what about men? Clinicians did not wait for formal approval – off-label use of the injectable PT-141 in men began in specialized centers, contributing to a growing body of real-world evidence. 

One recently reported study comes from a sexual medicine clinic that routinely prescribes bremelanotide off-label to men. In 2024, Goldstein and Goldstein published results from an observational study of 21 men with various sexual dysfunctions (low libido, ED, trouble with orgasm, etc.) who were given subcutaneous bremelanotide to use as needed. Key findings from this real-world survey include: 

• High Patient Satisfaction: After using PT-141 on at least two occasions, 80% of men reported being more satisfied with their lovemaking experience and its duration. Over 70% said that sex was more pleasurable for both themselves and their partner, and 86% felt more at ease initiating intimacy. This highlights significant improvements in confidence and reduction in performance anxiety.
• Improved Desire and Orgasm: Among those who responded well to therapy, 39% noted improvement in low sexual desire (male HSDD) and 52% noted improvement in their erectile dysfunction symptoms. About 17% even reported improvements in difficulty achieving orgasm. These numbers suggest bremelanotide’s benefits in men may extend beyond erections to broader sexual functioning (desire and climax).
• Global Improvement Scores: Using the Patient Global Impression of Improvement (PGI-I) scale, over half of the men (53%) initially, and up to 70% in an updated analysis, rated their sexual function as “a little better” to “very much better” after starting PT-141.In other words, a majority felt a noticeable overall improvement.
• Consistent Use (Refills): The clinic tracked prescription refill rates as a surrogate for efficacy/satisfaction. Men were refilling their bremelanotide prescriptions at much higher rates than women were (65% of dispensed prescriptions to men were refills, versus ~29–52% for women). Over an 18-month period, men had a 73% refill rate, indicating they found the treatment beneficial enough to continue long-term. This real-world adherence speaks to men perceiving value from PT-141 therapy.

It’s important to mention that the above was an uncontrolled study (no placebo group), but it provides a snapshot of outcomes in actual clinical use. The improvements in male patients’ desire, erectile function, and sexual satisfaction corroborate the mechanism we expect from PT-141’s central action.